← ADMA BIOLOGICS, INC.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | ($19.5m) |
($43.8m)
-124.23%
|
($65.7m)
-50.24%
|
($48.3m)
+26.56%
|
($75.7m)
-56.90%
|
($71.6m)
+5.41%
|
($65.9m)
+8.02%
|
($28.2m)
+57.15%
|
$197.7m
+800.00%
|
$146.9m
-25.67%
|
— | |
| Depreciation, Depletion and Amortization | $470k | $1.5m | $2.6m | $2.4m | $3.2m | $4.8m | $6.4m | $7.6m | $7.7m | $8.0m | $7.7m | |
| Amortization of Debt Issuance Costs | $0 | — | — | — | — | — | — | $0 | $0 | ($2.2m) | — | |
| Amortization of Intangible Assets | — | $1.2m | $845k | $845k | $715k | $715k | $715k | $724k | $388k | $144k | — | |
| Deferred Income Tax Expense (Benefit) | — | — | — | — | — | — | $0 | $0 | ($84.3m) | $11.0m | $9.3m | |
| Share-based Payment Arrangement, Noncash Expense | $1.3m | $1.6m | $2.2m | $2.7m | $2.9m | $3.5m | $5.2m | $6.2m | $13.6m | $20.0m | $22.9m | |
| Goodwill, Impairment Loss | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | |
| Nonoperating Income (Expense) | ($2.2m) | ($4.4m) | ($5.5m) | ($6.9m) | ($10.8m) | ($13.3m) | ($26.5m) | ($49.9m) | ($13.3m) | ($8.8m) | — | |
| Other Nonoperating Income (Expense) | — | ($10k) | ($127k) | ($227k) | ($129k) | ($252k) | ($634k) | ($287k) | ($193k) | ($212k) | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | $94k | $2.9m | ($2.5m) | $2.1m | ($9.8m) | $15.3m | ($13.1m) | $11.9m | $22.6m | $108.4m | ($28.5m) | |
| Increase (Decrease) in Inventories | $1.6m | ($589k) | $6.0m | $34.7m | ($28.5m) | $43.2m | $38.6m | $9.6m | ($2.7m) | $36.2m | ($47.8m) | |
| Increase (Decrease) in Accounts Payable | $477k | $2.8m | ($20k) | $3.3m | $1.9m | $1.4m | $800k | $3.8m | $4.2m | $2.3m | $1.8m | |
| Net Cash Provided by (Used in) Operating Activities | ($18.3m) |
($37.3m)
-104.02%
|
($62.7m)
-68.17%
|
($76.2m)
-21.56%
|
($102.0m)
-33.87%
|
($112.4m)
-10.16%
|
($59.5m)
+47.04%
|
$8.8m
+114.79%
|
$118.7m
+1248.55%
|
$50.4m
-57.53%
|
$136.7m
+171.29%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $73k | $2.7m | $2.1m | $3.8m | $12.7m | $13.5m | $13.9m | $4.8m | $8.2m | $22.6m | ($20.5m) | |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property | — | ($10k) | ($122k) | ($207k) | $82k | ($221k) | ($427k) | ($182k) | ($106k) | ($9k) | ($5.8m) | |
| Net Cash Provided by (Used in) Investing Activities | $905k | $15.2m | ($2.1m) | ($3.8m) | ($12.7m) | ($13.5m) | ($13.9m) | ($5.0m) | ($8.6m) | ($21.9m) | ($14.5m) | |
| Cash flows from financing activities: | ||||||||||||
| Repayments of Long-term Debt | — | — | — | — | $13.9m | — | — | — | — | — | ($76.9m) | |
| Gain (Loss) on Extinguishment of Debt | $0 | ($1.2m) | $0 | ($10.0m) | $992k | $0 | ($6.7m) | ($26.2m) | ($1.2m) | ($3.3m) | — | |
| Proceeds from Issuance of Long-term Debt | — | $30.0m | $0 | $72.5m | $27.5m | — | — | — | — | — | $200.0m | |
| Payments for Repurchase of Common Stock | — | — | — | — | — | — | — | — | — | $31.9m | — | |
| Proceeds from Issuance of Common Stock | $14.1m | $39.2m | $42.9m | $48.4m | $131.2m | $121.1m | $64.6m | $0 | $0 | — | $0 | |
| Net Cash Provided by (Used in) Financing Activities | $16.8m |
$60.8m
+260.79%
|
$42.9m
-29.35%
|
$80.0m
+86.39%
|
$143.9m
+79.86%
|
$121.0m
-15.88%
|
$108.9m
-10.08%
|
($39.0m)
-135.82%
|
($58.3m)
-49.53%
|
($44.0m)
+24.49%
|
($76.5m)
-73.75%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | ($526k) | $38.7m | ($21.9m) | ($3k) | $29.2m | ($4.8m) | $35.4m | ($35.2m) | $51.8m | ($15.5m) | $136.0m | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | $48.6m | $26.8m | $26.8m | — | $51.1m | $86.5m | $51.4m | $103.1m | $87.6m | $136.0m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | $0 | $8k | $13k | $75k | $13k | $0 | $175k | $1.1m | $7.5m | $3.0m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | $2.3m | $4.4m | $8.1m | $8.1m | $11.2m | $13.9m | $18.1m | $10.7m | $9.1m | — | |
| Income Taxes Paid, Net | — | — | — | — | $0 | ($62k) | ($2.9m) | ($1.4m) | ($5.0m) | $19.7m | — | |
| Additional Financial Items | ||||||||||||
| Gain (Loss) on Derivative Instruments, Net, Pretax | $0 | — | — | — | — | — | — | — | — | — | — | |
| General and Administrative Expense | $8.5m | $18.1m | $22.5m | $25.9m | $35.1m | — | — | — | — | — | — | |
| Goodwill | — | $3.5m | $3.5m | $3.5m | $3.5m | $3.5m | $3.5m | $3.5m | $3.5m | $3.5m | — | |
| Income Tax Expense (Benefit) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | ($72.0m) | $35.7m | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $13.9m | $7.1m | — | |
| Investment Income, Interest | — | — | — | — | $288k | $35k | $45k | $1.6m | $2.1m | $1.9m | — | |
| Operating Expenses | $28.0m | $62.1m | $77.3m | $70.8m | $107.1m | $59.5m | $74.6m | $67.3m | $80.6m | $101.3m | — | |
| Operating Lease, Expense | — | — | — | — | — | $1.4m | $2.1m | $2.4m | $2.4m | $2.4m | — | |
| Payments of Financing Costs | — | — | — | — | — | — | $2.8m | $2.4m | $0 | $0 | — |